Winrevair (sotatercept)

Manufacturer:
Merck
Route of Administration: 
Subcutaneous
Site of Care:
Outpatient
Website: 
  • Manufacturer Website
phone: 
888-637-2502

Approved Indication:

treatment of adults with pulmonary arterial hypertension (PAH, WHO group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events

Conditions:

  • Pulmonary Arterial Hypertension